Open AccessAzacitidine (Onureg)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.237
Subject(s) - reimbursement , azacitidine , medicine , myeloid leukemia , hematopoietic stem cell transplantation , intensive care medicine , transplantation , family medicine , political science , health care , biochemistry , gene expression , chemistry , dna methylation , gene , law
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.This review assesses azacitidine (Onureg), tablet 300 mg, oral.Indication: Maintenance therapy in adult patients with acute myeloid leukemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation.